Insider · CIK 0001662394

Ward Keith Wayne

Reports to the SEC for 2 companies · IRVING, TX

sec.gov

Transactions

Companies

Filings

CIK

0001662394

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2024-02-29	SKYESkye Bioscience, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+35K sh	—	—	35,000
2023-11-06	SKYESkye Bioscience, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+14.1K sh	—	—	20,001
2023-08-25	SKYESkye Bioscience, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+1.47M sh	—	—	1,472,692
2023-01-05	SKYESkye Bioscience, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+250K sh	—	—	250,000
2021-12-14	SKYESkye Bioscience, Inc. · Director Option Grant (Right to Buy)A Award	Director	AAward	+250K sh	—	—	250,000
2019-02-26	REATA PHARMACEUTICALS INCC Conversion	Chief Development Officer	CConversion	+25.2K sh	—	—	33,804
2019-02-26	REATA PHARMACEUTICALS INCS Sale	Chief Development Officer	SSale	−16.8K sh	$91.00	−$1.53M	16,987
2019-02-26	REATA PHARMACEUTICALS INCS Sale	Chief Development Officer	SSale	−8,367 sh	$91.62	−$767K	8,620
2019-02-26	REATA PHARMACEUTICALS INCEmployee Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−16.8K sh	—	—	76,150
2019-02-26	REATA PHARMACEUTICALS INCEmployee Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−8,367 sh	—	—	0
2019-02-26	REATA PHARMACEUTICALS INCClass B common stockM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+16.8K sh	$11.00	+$185K	16,817
2019-02-26	REATA PHARMACEUTICALS INCClass B common stockM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+8,367 sh	$11.62	+$97.2K	25,184
2019-02-26	REATA PHARMACEUTICALS INCClass B common stockC Conversion	Chief Development Officer	CConversion	−25.2K sh	—	—	0
2019-02-25	REATA PHARMACEUTICALS INCC Conversion	Chief Development Officer	CConversion	+15.2K sh	—	—	23,803
2019-02-25	REATA PHARMACEUTICALS INCS Sale	Chief Development Officer	SSale	−15.2K sh	$91.00	−$1.38M	8,620
2019-02-25	REATA PHARMACEUTICALS INCEmployee Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−15.2K sh	—	—	92,967
2019-02-25	REATA PHARMACEUTICALS INCClass B common stockM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+15.2K sh	$11.00	+$167K	15,183
2019-02-25	REATA PHARMACEUTICALS INCClass B common stockC Conversion	Chief Development Officer	CConversion	−15.2K sh	—	—	0
2019-01-31	REATA PHARMACEUTICALS INCC Conversion	Chief Development Officer	CConversion	+4,150 sh	—	—	12,770
2019-01-31	REATA PHARMACEUTICALS INCS Sale	Chief Development Officer	SSale	−1,400 sh	$76.17	−$107K	11,370
2019-01-31	REATA PHARMACEUTICALS INCS Sale	Chief Development Officer	SSale	−2,750 sh	$76.97	−$212K	8,620
2019-01-31	REATA PHARMACEUTICALS INCEmployee Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−4,150 sh	—	—	8,367
2019-01-31	REATA PHARMACEUTICALS INCClass B common stockM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+4,150 sh	$11.62	+$48.2K	4,150
2019-01-31	REATA PHARMACEUTICALS INCClass B common stockC Conversion	Chief Development Officer	CConversion	−4,150 sh	—	—	0
2019-01-14	REATA PHARMACEUTICALS INCC Conversion	Chief Development Officer	CConversion	+8,620 sh	—	—	8,620
2019-01-14	REATA PHARMACEUTICALS INCEmployee Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−8,620 sh	—	—	12,517
2019-01-14	REATA PHARMACEUTICALS INCClass B common stockM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+8,620 sh	$11.62	+$100K	8,620
2019-01-14	REATA PHARMACEUTICALS INCClass B common stockC Conversion	Chief Development Officer	CConversion	−8,620 sh	—	—	0
2019-01-02	REATA PHARMACEUTICALS INCEmployee Stock Option (right to buy)A Award	Chief Development Officer	AAward	+34.5K sh	—	—	34,500
2019-01-02	REATA PHARMACEUTICALS INCC Conversion	Chief Development Officer	CConversion	+4,150 sh	—	—	4,150
2019-01-02	REATA PHARMACEUTICALS INCS Sale	Chief Development Officer	SSale	−2,830 sh	$53.71	−$152K	1,320
2019-01-02	REATA PHARMACEUTICALS INCS Sale	Chief Development Officer	SSale	−1,320 sh	$54.58	−$72K	0
2019-01-02	REATA PHARMACEUTICALS INCEmployee Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−4,150 sh	—	—	21,137
2019-01-02	REATA PHARMACEUTICALS INCClass B common stockM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+4,150 sh	$11.62	+$48.2K	4,150
2019-01-02	REATA PHARMACEUTICALS INCClass B common stockC Conversion	Chief Development Officer	CConversion	−4,150 sh	—	—	0
2018-11-07	REATA PHARMACEUTICALS INCC Conversion	Chief Development Officer	CConversion	+4,750 sh	—	—	4,750
2018-11-07	REATA PHARMACEUTICALS INCS Sale	Chief Development Officer	SSale	−3,697 sh	$66.64	−$246K	1,053
2018-11-07	REATA PHARMACEUTICALS INCS Sale	Chief Development Officer	SSale	−1,053 sh	$68.13	−$71.7K	0
2018-11-07	REATA PHARMACEUTICALS INCEmployee Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−4,750 sh	—	—	25,287
2018-11-07	REATA PHARMACEUTICALS INCClass B common stockM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+4,750 sh	$11.62	+$55.2K	4,750
2018-11-07	REATA PHARMACEUTICALS INCClass B common stockC Conversion	Chief Development Officer	CConversion	−4,750 sh	—	—	0
2018-11-01	REATA PHARMACEUTICALS INCC Conversion	Chief Development Officer	CConversion	+4,750 sh	—	—	4,750
2018-11-01	REATA PHARMACEUTICALS INCS Sale	Chief Development Officer	SSale	−4,750 sh	$59.48	−$283K	0
2018-11-01	REATA PHARMACEUTICALS INCEmployee Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−4,750 sh	—	—	30,037
2018-11-01	REATA PHARMACEUTICALS INCClass B common stockM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+4,750 sh	$11.62	+$55.2K	4,750
2018-11-01	REATA PHARMACEUTICALS INCClass B common stockC Conversion	Chief Development Officer	CConversion	−4,750 sh	—	—	0
2018-10-23	REATA PHARMACEUTICALS INCC Conversion	Chief Development Officer	CConversion	+14.3K sh	—	—	14,250
2018-10-23	REATA PHARMACEUTICALS INCS Sale	Chief Development Officer	SSale	−14.3K sh	$57.08	−$813K	0
2018-10-23	REATA PHARMACEUTICALS INCEmployee Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−14.3K sh	—	—	34,787
2018-10-23	REATA PHARMACEUTICALS INCClass B common stockM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+14.3K sh	$11.62	+$166K	14,250

Recent filings

Accepted (ET)
Mar 44
Ward Keith Wayne0001516551-24-000025
SEC(opens sec.gov)
Nov 64
Ward Keith Wayne0001516551-23-000098
SEC(opens sec.gov)
Aug 294
Ward Keith Wayne0001516551-23-000056
SEC(opens sec.gov)
Jan 94
Ward Keith Wayne0001516551-23-000010
SEC(opens sec.gov)
Dec 164
Ward Keith Wayne0001516551-21-000025
SEC(opens sec.gov)
Feb 274
Ward Keith Wayne0001209191-19-014057
SEC(opens sec.gov)
Feb 14
Ward Keith Wayne0001209191-19-006341
SEC(opens sec.gov)

Companies

Address

2801 GATEWAY DRIVE, SUITE 150

IRVING, TX, 75063